Stockscreener 앱 받기
5.36
0.92%
-0.05
시간 외 거래:
5.38
0.02
+0.37%
전일 마감가:
$5.41
열려 있는:
$5.45
하루 거래량:
11.91M
Relative Volume:
0.44
시가총액:
$2.14B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-3.4581
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
-5.63%
1개월 성능:
+0.00%
6개월 성능:
-28.44%
1년 성능:
-19.28%
1일 변동 폭
$5.35
$5.58
1주일 범위
$5.28
$5.96
52주 변동 폭
$3.79
$12.36
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.36 | 2.38B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - The Motley Fool
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - MSN
Recursion Bets Big On AI-Driven Drug Discovery, But Losses Mount - Finimize
Recursion outlines $100M partnership inflows target by end of 2026 as cash runway extends through Q4 2027 - MSN
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - MSN
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript - MSN
Why Recursion Pharmaceuticals Stock Tanked on Tuesday - Mitrade
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week - 富途牛牛
Recursion Pharmaceuticals Reports Q2 Loss, Beats Revenue Estimates - AInvest
Broker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - ca.finance.yahoo.com
Recursion Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Recursion Pharmaceuticals shares fall 1.99% premarket after reporting a wider Q2 loss. - AInvest
Recursion Pharmaceuticals: Q2 Earnings Snapshot - Stamford Advocate
Recursion Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Recursion (RXRX) Q2 Revenue Jumps 33% - AOL.com
Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks
Recursion Pharmaceuticals: Balancing AI Advancements with Financial Prudence Justifies Hold Rating - TipRanks
Recursion Pharmaceuticals and Biodexa: A High-Stakes Race in the FAP Market - AInvest
Recursion Pharmaceuticals: Strong Financial Position and Strategic Focus Justify Buy Rating - TipRanks
Recursion's Q2 2025 Earnings Call: Unpacking Key Contradictions in Strategy and Innovation - AInvest
Recursion Pharmaceuticals (RXRX): A Deep Dive into Platform-Driven Value Creation and Strategic Milestone Potential in 2025 - AInvest
Recursion Pharmaceuticals sets $100M partnership inflows target by 2026, extends cash runway to Q4 2027 - AInvest
Pharma Boom: RXRX Stocks Soar After Latest Innovation - timothysykes.com
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates - MSN
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates - Benzinga
Recursion Pharmaceuticals reports Q2 EPS (41c), consensus (35c) - TipRanks
Earnings call transcript: Recursion Pharmaceuticals Q2 2025 sees revenue beat - Investing.com
Recursion Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Up 50% in 3 Months, Is This Stock Still a Buy? - AOL.com
Recursion Pharmaceuticals Fiscal Q2 Loss Widens, Revenue Rises - MarketScreener
Recursion Pharmaceuticals shares rise 4.31% premarket after reporting revenue of $19.2 million, exceeding expectations. - AInvest
Why Recursion Pharmaceuticals Shares Are Gaining Momentum - TipRanks
Recursion Pharmaceuticals earnings missed by $0.06, revenue topped estimates - Investing.com Australia
RECURSION PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Earnings Flash (RXRX) Recursion Pharmaceuticals Inc Reports Q2 Revenue $19.2M, vs. FactSet Est of $15.4M - MarketScreener
Recursion Reports Q2 Financial Results, Deploys Advanced Models for Medicine Discovery. - AInvest
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards? - MSN
Recursion Pharmaceuticals Earnings Preview - 富途牛牛
Recursion Pharmaceuticals Q2 2025 Earnings: A TechBio Inflection Point? - AInvest
Two Biotech Stocks with High Upside Potential: Viking Therapeutics and Recursion Pharmaceuticals - AInvest
What catalysts could drive Recursion Pharmaceuticals Inc. stock higher in 2025Maximize portfolio growth with professional advice - Jammu Links News
Why is Recursion Pharmaceuticals Inc. stock attracting strong analyst attentionExpert guidance for superior capital growth - Jammu Links News
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):